As mutations in TSC1 and TSC2, which cause partial-onset seizures associated with TSC, were found in focal cortical dysplasia type II (FCD II) patients, a clinical trial has been performed to explore the efficacy and safety of everolimus in FCD patients. This evidence concerns the gene TSC2 and tuberous sclerosis.